manufacture supply CAS 2364554-48-1 Aficamten Ck-274

99% Powder CAS 2364554-48-1 Aficamten Ck-274

Introduction:

Primary Function: Cardiac Myosin Inhibitor

• Directly Target Cardiac Myosin:​ It binds to the protein myosin in heart muscle cells (cardiomyocytes), specifically to the S1 domain of beta-cardiac myosin.
• Reduce Hypercontractility:​ By binding to myosin, it decreases the number of active myosin heads available to interact with actin. This leads to a dose-dependent reduction in the excessive force generation (hypercontractility)​ and impaired relaxation that are hallmarks of certain heart diseases.
• Improve Energetics:​ It is believed to lower the heart's excessive energy demand and improve cardiac efficiency by stabilizing myosin in a low-energy state.

Primary Application: Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM)

• Mechanism in oHCM:​ In oHCM, a thickened heart muscle (septum) obstructs blood flow out of the left ventricle. The hypercontractility worsens this obstruction. Aficamten reduces this hypercontractility, thereby:
  • Reducing Left Ventricular Outflow Tract Gradient (LVOT-G):​ It directly lowers the pressure gradient caused by the obstruction, which is a key measure of disease severity.
  • Improving Symptoms:​ Clinical trials (such as the REDWOOD-HCM​ and SEQUOIA-HCM​ trials) have shown that Aficamten significantly improves exercise capacity (measured by peak oxygen uptake, pVO₂), reduces symptoms like shortness of breath (dyspnea) and chest pain (angina), and enhances overall functional status (NYHA Class).
  • Favorable Safety Profile:​ It has been designed to have a shorter half-life​ than some earlier-generation myosin inhibitors, allowing for more rapid dose titration and potentially mitigating the risk of excessive contractility reduction (leading to heart failure).

Other Potential Applications (Under Investigation)

• Non-Obstructive Hypertrophic Cardiomyopathy (nHCM):​ Studies are ongoing to evaluate its benefits in patients with HCM but without significant outflow obstruction.
• Other Cardiomyopathies:​ Preclinical and early clinical research may investigate its utility in conditions where modulating myosin contractility could be beneficial.

Q1: Are you the manufacturer or trade company?
--We are the manufacturer in China, founded on 2011.

Q2: When will the product be shipped after payment?
--The parcel will be get ready and shipped within 1 day.

Q3: How long will it take to receive the parcel?
--3-5days for the US market; 3-7days for the others.

Q4: What can I do if I don't have the ability to clear the custom.
--We got experience after doing export for many years, so don't worry we can handle that.

Q5: Why should you buy from us not from other suppliers?
---Jinan Jianfeng Chemical Co.,Ltd is a medium-sized enterprise integrating the development, production, sales and export and import trade of chemical products. Our factory has perfect infrastructure, advanced processing technology and completed detection means.